Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03206931
Expanded Access Status : No longer available
First Posted : July 2, 2017
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Condition or disease Intervention/treatment
Solid Tumors Harboring NTRK Fusion Drug: Selitrectinib (BAY2731954)

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Selitrectinib (BAY2731954)
    Selitrectinib is administered as capsules or liquid formulation.
    Other Name: Loxo-195

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
  • Previous treatment with a kinase inhibitor with known activity on TRK inhibition
  • Unable to participate in an ongoing selitrectinib clinical trial
  • Medically suitable for treatment with selitrectinib

Exclusion Criteria:

  • Currently enrolled in an ongoing clinical study with a TRK inhibitor

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03206931    
Other Study ID Numbers: 21002
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Keywords provided by Bayer:
Metastatic cancer
Advanced cancer
Neurotrophic tyrosine receptor kinase (NTRK)
NTRK1
NTRK2
NTRK3
Fusion Positive
Children
Loxo-195
Additional relevant MeSH terms:
Layout table for MeSH terms
Selitrectinib
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action